Literature DB >> 11684957

The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.

B Davidson1, S Nielsen, J Christensen, P Asschenfeldt, A Berner, B Risberg, P Johansen.   

Abstract

The objective of the present study was to analyze the role of the mesothelial markers desmin and N-cadherin in the diagnostic panel of serous effusions. A total of 181 pleural and peritoneal effusions consisted of 101 cases cytologically diagnosed as malignant (89 carcinomas, 12 mesotheliomas), 78 benign, and 2 inconclusive specimens. All specimens were immunostained using 11 antibodies, against epithelial membrane antigen, Ber-EP4, carcinoembryonic antigen, E-cadherin, CA 125, N-cadherin, desmin, calretinin, p53, vimentin, and CD45. After evaluation of immunocytochemistry results, 110 specimens were diagnosed as malignant (98 carcinomas, 12 mesotheliomas) and 71 as benign (56 cellular, 15 paucicellular). The presence of desmin was detected in benign mesothelial cells in 47 of 56 (84%) reactive cellular specimens compared with 1 of 12 (8%) malignant mesotheliomas and 2 of 98 (2%) carcinomas. N-cadherin was expressed in 48 of 56 (86%) reactive cases, 12 of 12 (100%) mesotheliomas, and 47 of 98 (48%) carcinomas. In carcinomas, N-cadherin expression was most often seen in ovarian carcinoma but was also found in other carcinomas. Calretinin, an established marker of mesothelial cells, was detected in 52 of 56 (93%) reactive specimens, 11 of 12 (93%) mesotheliomas, and 3 of 98 (3%) carcinomas. Evaluation of staining results led to reclassification of six malignant specimens as benign, whereas 17 cases diagnosed as benign and the two diagnosed as inconclusive were classified as malignant. In conclusion, desmin appears to be a promising marker for the distinction between reactive mesothelium and malignant epithelial cells in terms of both specificity and sensitivity, and its complementary use with calretinin is recommended. Unlike calretinin, it may also prove valuable for the distinction between benign and malignant mesothelial cells. N-cadherin does not have a role in the distinction between mesothelial and epithelial cells. However, it may prove useful in the characterization of carcinomas of unknown origin. As has previously been shown, a significant number of diagnoses that are based on morphologic examination alone are modified after the use of a broad antibody panel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684957     DOI: 10.1097/00000478-200111000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  22 in total

1.  PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.

Authors:  Y Yuan; H P Dong; D A Nymoen; J M Nesland; C Wu; B Davidson
Journal:  Cytopathology       Date:  2011-02       Impact factor: 2.073

2.  Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.

Authors:  Geoffrey Kim; Ben Davidson; Ryan Henning; Junbai Wang; Minshu Yu; Christina Annunziata; Thea Hetland; Elise C Kohn
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

3.  HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Authors:  Thea Eline Hetland; Arild Holth; Janne Kærn; Vivi Ann Flørenes; Claes G Tropé; Ben Davidson
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

4.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

5.  Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.

Authors:  Jean-Pierre Gillet; Junbai Wang; Anna Maria Calcagno; Lisa J Green; Sudhir Varma; Mari Bunkholt Elstrand; Claes G Trope; Suresh V Ambudkar; Ben Davidson; Michael M Gottesman
Journal:  Mol Pharm       Date:  2011-07-15       Impact factor: 4.939

6.  Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions.

Authors:  Ben Davidson; Tian-Li Wang; Ie-Ming Shih; Aasmund Berner
Journal:  Hum Pathol       Date:  2008-03-04       Impact factor: 3.466

7.  Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions.

Authors:  Daniel E Schwed Lustgarten; Jeffrey Thompson; Gordon Yu; Anil Vachani; Bhavesh Vaidya; Chandra Rao; Mark Connelly; Michelle Udine; Kay See Tan; Daniel F Heitjan; Steven Albelda
Journal:  Ann Am Thorac Soc       Date:  2013-12

8.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.

Authors:  Lilach Kleinberg; Vivi Ann Flørenes; Martina Skrede; Hiep Phuc Dong; Søren Nielsen; Michael T McMaster; Jahn M Nesland; Ie-Ming Shih; Ben Davidson
Journal:  Virchows Arch       Date:  2006-03-16       Impact factor: 4.064

9.  Tenascin-X is a novel diagnostic marker of malignant mesothelioma.

Authors:  Yuan Yuan; Dag André Nymoen; Helene Tuft Stavnes; Anne Katrine Rosnes; Ola Bjørang; Chuanyue Wu; Jahn M Nesland; Ben Davidson
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

10.  Breast carcinoma cells in primary tumors and effusions have different gene array profiles.

Authors:  Sophya Konstantinovsky; Yoav Smith; Sofia Zilber; Helene Tuft Stavnes; Anne-Marie Becker; Jahn M Nesland; Reuven Reich; Ben Davidson
Journal:  J Oncol       Date:  2009-08-11       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.